Home › Funds › Vestal Point Capital, LP › LXEO
Vestal Point Capital, LP position in LXEO
LEXEO THERAPEUTICS INC COM · Health Care
Vestal Point Capital, LP reported holding 4,320,000 shares of LXEO (LEXEO THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$20.1M, representing 0.47% of its reported portfolio and ranking #45 among its reported holdings. Vestal Point Capital, LP has disclosed LXEO holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's LXEO position evolved
Vestal Point Capital, LP first disclosed a stake in LXEO in Q1 2024 at 175,000 shares (US$2.7M). The position peaked in Q4 2025 at 4,475,000 shares, worth US$44.4M. Across 10 filings, Vestal Point Capital, LP increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 4,320,000 shares valued at US$20.1M — a reduction of -155,000 shares quarter over quarter.. Notable position changes include a 380% increase in Q2 2024 (shares fell 59% over the following quarter), a 41% increase in Q4 2024 (shares fell 47% over the following quarter), a 184% increase in Q2 2025 (shares rose 65% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 175.00K | $2.74M | New |
| Q2 2024 | 840.00K | $13.47M | Add |
| Q3 2024 | 850.00K | $7.68M | Add |
| Q4 2024 | 1.20M | $7.90M | Add |
| Q1 2025 | 1.14M | $3.94M | Reduce |
| Q2 2025 | 3.23M | $12.98M | Add |
| Q3 2025 | 3.25M | $21.58M | Add |
| Q4 2025 | 4.47M | $44.44M | Add |
| Q1 2026 | 4.47M | $25.69M | Hold |
| Q2 2026 | 4.32M | $20.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LXEO and 13F data
LXEO (LEXEO THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LXEO
- MONTANOVA CAPITAL, LLC 6.38M sh · $29.72M · Q2 2026
- Affinity Asset Advisors, LLC 5.81M sh · $27.03M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.82M sh · $22.46M · Q2 2026
- Paradigm Biocapital Advisors LP 4.18M sh · $19.44M · Q2 2026
- 683 Capital Management, LLC 1.88M sh · $8.73M · Q2 2026
- Avoro Capital Advisors LLC 1.49M sh · $6.93M · Q2 2026
- Spruce Street Capital LP 928.59K sh · $4.32M · Q2 2026
- DAFNA Capital Management LLC 377.06K sh · $1.76M · Q2 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held LXEO?
Vestal Point Capital, LP has disclosed LXEO holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is Vestal Point Capital, LP's current position in LXEO?
As of Q2 2026, Vestal Point Capital, LP holds 4.32M shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $20.11M, representing 0.47% of its reported portfolio and ranking #45.
Has Vestal Point Capital, LP been buying or selling LXEO?
In the latest 13F filing (Q2 2026), Vestal Point Capital, LP reduced its position in LXEO. The position peaked in Q4 2025 at 4.47M shares.
Which other funds hold LXEO?
Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.